Prostate Cancer: Screening
Commons · Question 100314 · Tabled 16 Dec 2025 · Department of Health and Social Care · Official record
Answered 14 Jan 2026
Question
Asked by Jim Shannon
To ask the Secretary of State for Health and Social Care, what assessment he has been made of the adequacy of national production capacity for PSMA radiotracers in the context of projected clinical demand for prostate cancer diagnosis.
Answer
Answered by Ashley Dalton, 14 Jan 2026
Prostate-specific membrane antigen (PSMA) radiotracers are commissioned for use as part of PET-CT prostate cancer imaging, as set out in the published clinical commissioning policy. Access to PET-CT, as with any healthcare service, is closely monitored.